Pain Medication Questionnaire (PMQ)
PMQ scoring guide. Pain Medication Questionnaire — 26-item opioid misuse risk screen for chronic pain. Score ≥23 = elevated risk. Adams et al. 2004.
Foundational Context
Chronic pain treatment often requires balancing analgesic benefit with the risks associated with prescription opioids. The PMQ was created to improve early detection of patients who may be at greater risk for medication misuse. Its item set captures known psychosocial correlates of opioid-related risk, including:
- Preoccupation with medication
- Past substance misuse
- Pain-related distress
- Inconsistent adherence
- Emotional or behavioural responses to opioid use
Unlike some risk tools based solely on clinician ratings or historical factors, the PMQ centers patient self-report to reveal attitudes and behaviors that may not appear in chart reviews. The tool supplements, rather than replaces, clinical judgment and comprehensive assessment.
What the Assessment Measures
The PMQ evaluates behavioural and psychological factors associated with opioid misuse risk:
- Concerns about access to medication
- Worry over inadequate dosing
- Tendency to self-adjust doses
- Using medication to cope emotionally
- History of substance use
- Inconsistent or maladaptive adherence behavior
- Pain-related distress and frustration
All items contribute to one summed risk score.
Interpretation Guidelines
Scores reflect the overall level of opioid misuse risk factors:
- Range: 26–130
- Higher scores → higher risk
- Common research-supported threshold:
- ≥30–33 associated with elevated risk for aberrant medication-related behaviors
Interpretation Notes:
- No diagnostic function, scores indicate risk, not confirmed misuse
- Thresholds vary across populations and settings
- Should be integrated with broader assessments, including:
- Clinical interviews
- Prescription monitoring programs
- Collateral information
- Pain/function measures
- Elevated scores warrant closer monitoring, structured opioid agreements, or alternative pain-management planning
Psychometric Properties
Reliability
- Good internal consistency across the 26 items
- Stable factor structure related to psychosocial risk dimensions
Validity
- Predictive validity demonstrated for aberrant medication behaviors
- Correlates with clinician-observed risk indicators
- Good sensitivity for high-risk populations
- Not validated as a diagnostic measure for substance use disorders
Administration Considerations
- Straightforward self-report, easy to administer in clinical settings
- Must be interpreted within a harm-reduction and non-stigmatizing framework
- Elevated scores do not imply noncompliance or wrongdoing, risk factors are multifactorial
- Should not influence prescribing decisions without corroborating assessment
- Useful as part of multidisciplinary pain management
Limitations
- Risk assessment only, does not detect actual misuse
- Self-report may be influenced by stigma or fear of medication restriction
- Some items overlap with legitimate concerns of chronic pain patients
- Cultural and contextual factors may influence responses
- Should not be used in isolation to deny treatment or determine culpability
Pain Medication Questionnaire (PMQ) Overview
Validated 26-item self-report screen for opioid misuse risk in chronic pain patients. Used before initiating or continuing long-term opioid therapy.
26 items × 0–4 scale. Total score range: 0–104. Cutoff ≥23 = elevated risk.
Important: PMQ scores are risk indicators, not prescribing mandates. A score ≥23 warrants enhanced monitoring, it does not justify withholding pain treatment. Use in conjunction with PDMP review, clinical interview, and urine drug screening as part of a thorough risk management approach.
PMQ vs ORT vs SOAPP-R
Three validated opioid misuse risk screeners, each with different trade-offs.
Recommended approach: No single screener is sufficient alone. Many pain programs use the ORT for rapid initial triage and the PMQ or SOAPP-R for detailed pre-prescribing evaluation. Using two tools with different methodologies (clinician vs self-report) reduces response bias and improves overall risk stratification accuracy.
Documenting PMQ Results in Clinical Notes
Record the PMQ total score, risk category, and any elevated domain scores in the Objective section. Document the clinical response to elevated risk (e.g., enhanced monitoring plan, PDMP review date).
Frequently Asked Questions
Is the PMQ self-report or clinician-administered?
The PMQ is a self-report instrument completed by the patient. This distinguishes it from clinician-administered tools such as the Opioid Risk Tool (ORT) and allows patients to disclose attitudes and behaviours they may be less willing to share directly with a prescriber. Self-report format also makes it practical for routine pre-prescribing screening in outpatient pain settings.
Can the PMQ diagnose opioid use disorder?
No. The PMQ is a risk screener, not a diagnostic tool. It identifies psychosocial factors associated with a higher likelihood of aberrant medication-related behaviours, but a diagnosis of opioid use disorder requires a structured clinical assessment using DSM-5 or ICD-11 criteria. An elevated PMQ score should prompt closer monitoring and a thorough clinical evaluation, not automatic attribution of a diagnosis.
What constructs does the PMQ measure?
The 26 items of the PMQ capture four overlapping psychosocial domains: attitudes toward medication and perceived need for opioids; social support and relational context; personal history including prior substance use and treatment adherence; and behavioural patterns such as dose self-adjustment and emotional reliance on medication. All items contribute to a single summed risk score rather than separate subscale totals.
How well does the PMQ predict aberrant drug-related behaviour?
A revised and shortened version of the PMQ demonstrated 85.5% predictive accuracy for identifying aberrant medication behaviour in a heterogeneous chronic pain sample (Buelow et al., 2009). A 2017 systematic review of 14 validated opioid risk tools concluded that the PMQ and the SOAPP had the strongest evidence base for predicting prescription opioid misuse, each validated across four or more studies of acceptable quality (Lawrence et al., 2017).
References
- 1.Adams LL, Gatchel RJ, Robinson RC, Polatin P, Gajraj N, Deschner M, Noe C. Development of a self-report screening instrument for assessing potential opioid medication misuse in chronic pain patients. J Pain Symptom Manage. 2004;27(5):440-459.View source
- 2.Buelow AK, Haggard R, Gatchel RJ. Additional validation of the pain medication questionnaire in a heterogeneous sample of chronic pain patients. Pain Pract. 2009;9(6):428-434.View source
- 3.Lawrence R, Mogford D, Colvin L. Systematic review to determine which validated measurement tools can be used to assess risk of problematic analgesic use in patients with chronic pain. Br J Anaesth. 2017;119(6):1092-1109.View source
Bill this assessment
The Pain Medication Questionnaire (PMQ) qualifies for reimbursement under these CPT codes (US).
Last reviewed: Jun 3, 2026
Related Assessments
Explore complementary clinical tools and screeners